New hope for myelofibrosis: experimental drug selinexor takes on enlarged spleens and symptoms
NCT ID NCT04562870
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 28 times
Summary
This study tests a drug called selinexor against the doctor's choice of treatment for people with myelofibrosis, a rare bone marrow disorder. Participants must have already tried a JAK inhibitor for at least 6 months. The main goal is to see if selinexor can shrink the spleen and improve symptoms better than other available options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi
Varese, 21100, Italy
-
Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti
Latina, 4100, Italy
-
Centre Hospitalier Universitaire d'Angers (CHU Angers)
Angers, 49933, France
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Illinois Cancer Specialist
Niles, Illinois, 60714, United States
-
Institut de Cancéro-Hématologie
Brest, Brittany Region, 29609, France
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Meldola, Forlì-Cesena, 47014, Italy
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Pratia Onkologia Katowice
Katowice, 40-519, Poland
-
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado, 80012, United States
-
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
Suzhou University -The First Affiliated Hospital
Suzhou, Jiangsu, 215007, China
-
Texas Oncology - Northeast Texas
Tyler, Texas, 75702, United States
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Oncology Institute of Hope and Innovation
Pasadena, California, 91105, United States
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
University General Hospital "ATTIKON"
Athens, Attica, 12462, Greece
-
University of Perugia Department of Medicine Hematology Section
Perugia, 6132, Italy
-
Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica
Florence, 50134, Italy
Conditions
Explore the condition pages connected to this study.